136 related articles for article (PubMed ID: 21861853)
1. Estrogen receptor degradation: a CUE for endocrine resistance?
Musgrove EA
Breast Cancer Res; 2011 Aug; 13(4):312. PubMed ID: 21861853
[TBL] [Abstract][Full Text] [Related]
2. Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer.
Pan X; Zhou T; Tai YH; Wang C; Zhao J; Cao Y; Chen Y; Zhang PJ; Yu M; Zhen C; Mu R; Bai ZF; Li HY; Li AL; Liang B; Jian Z; Zhang WN; Man JH; Gao YF; Gong WL; Wei LX; Zhang XM
Nat Med; 2011 Jun; 17(6):708-14. PubMed ID: 21572428
[TBL] [Abstract][Full Text] [Related]
3. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.
Arpino G; Wiechmann L; Osborne CK; Schiff R
Endocr Rev; 2008 Apr; 29(2):217-33. PubMed ID: 18216219
[TBL] [Abstract][Full Text] [Related]
4. Modulation of estrogen receptor alpha protein level and survival function by DBC-1.
Trauernicht AM; Kim SJ; Kim NH; Boyer TG
Mol Endocrinol; 2007 Jul; 21(7):1526-36. PubMed ID: 17473282
[TBL] [Abstract][Full Text] [Related]
5. A CUE hints at tumor resistance.
Thomas C; Gustafsson JA
Nat Med; 2011 Jun; 17(6):658-60. PubMed ID: 21647141
[No Abstract] [Full Text] [Related]
6. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity.
Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura A; Lawrence J; Berstein L; Yue W
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S61-73. PubMed ID: 16113100
[TBL] [Abstract][Full Text] [Related]
7. A Novel Functional Domain of Tab2 Involved in the Interaction with Estrogen Receptor Alpha in Breast Cancer Cells.
Reineri S; Agati S; Miano V; Sani M; Berchialla P; Ricci L; Iannello A; Coscujuela Tarrero L; Cutrupi S; De Bortoli M
PLoS One; 2016; 11(12):e0168639. PubMed ID: 27992601
[TBL] [Abstract][Full Text] [Related]
8. ERα-targeted endocrine therapy, resistance and the role of GPER.
Pepermans RA; Prossnitz ER
Steroids; 2019 Dec; 152():108493. PubMed ID: 31518595
[TBL] [Abstract][Full Text] [Related]
9. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptors in breast carcinogenesis and endocrine therapy.
Huang B; Warner M; Gustafsson JÅ
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():240-4. PubMed ID: 25433206
[TBL] [Abstract][Full Text] [Related]
11. Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.
Roop RP; Ma CX
Future Oncol; 2012 Mar; 8(3):273-92. PubMed ID: 22409464
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a multi-target compound for estrogen receptor-positive (ER
Almeida CF; Teixeira N; Oliveira A; Augusto TV; Correia-da-Silva G; Ramos MJ; Fernandes PA; Amaral C
Biochimie; 2021 Feb; 181():65-76. PubMed ID: 33278557
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.
Normanno N; Di Maio M; De Maio E; De Luca A; de Matteis A; Giordano A; Perrone F;
Endocr Relat Cancer; 2005 Dec; 12(4):721-47. PubMed ID: 16322319
[TBL] [Abstract][Full Text] [Related]
14. Intratumoural inflammation and endocrine resistance in breast cancer.
Murray JI; West NR; Murphy LC; Watson PH
Endocr Relat Cancer; 2015 Feb; 22(1):R51-67. PubMed ID: 25404688
[TBL] [Abstract][Full Text] [Related]
15. Cancer Navigation Strategy for Endocrine Therapy-Resistant Breast Tumors.
Nakao M; Fujiwara S; Iwase H
Trends Cancer; 2018 Jun; 4(6):404-407. PubMed ID: 29860984
[TBL] [Abstract][Full Text] [Related]
16. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
17. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
18. Molecular basis of therapeutic strategies for breast cancer.
Huang J; Li X; Hilf R; Bambara RA; Muyan M
Curr Drug Targets Immune Endocr Metabol Disord; 2005 Dec; 5(4):379-96. PubMed ID: 16375692
[TBL] [Abstract][Full Text] [Related]
19. Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.
Lu Y; Liu W
J Med Chem; 2020 Dec; 63(24):15094-15114. PubMed ID: 33138369
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]